Skip to main content

Market Overview

Hold On Teladoc Bulls: Stifel Is Cautious Amid Business Model Uncertainty

Hold On Teladoc Bulls: Stifel Is Cautious Amid Business Model Uncertainty

On Wednesday, Stifel issued its "Morning Research Summary" and initiated Coverage on Teladoc Inc (NYSE: TDOC). Currently, Stifel rates Teladoc as Hold with no attached price target listed.

Stifel views telemedicine as an attractive investment opportunity; however, Stifel analyst Steven Rubis wrote, "While we respect management and believe Teladoc faces a significant growth runway, we believe there are several risk factors that outweigh the positives [...] We believe we need to seek greater clarity around our primary concerns and more attractive valuation levels before potentially becoming constructive, all else being equal."

Related Link: Meet 2015's Best Healthcare ETF

Telemedicine And Teladoc

Stifel highlighted five key risks that make the firm cautious on Teladoc:

  • 1. Teladoc's business model may be more costly than an in-person visit.
  • 2. There is a high amount of competition in the telemedicine sector.
  • 3. The market for visits may be more limited than Teladoc's management has led investors to believe.
  • 4. There are concerns over both revenue and revenue growth and poor utilization rates.
  • 5. Sky-high earnings expectations with the majority of price targets being double the current share price>

Overall, while telemedicine represents a potentially attractive investment opportunity, concerns over Teladoc's business model, increased competition and a limited market of users makes Stifel question the strength of Teladoc going forward.

With that in mind, the firm says that they cannot justify valuing Teladoc higher than competitors Medidata Solutions Inc (NASDAQ: MDSO) and athenahealth, Inc (NASDAQ: ATHN).

Recent Trading Activity

Athenahealth was recently seen trading down 0.78 percent at $161.95.

Medidata was recently seen trading up 0.31 percent at $48.20.

Teladoc was recently seen trading up 0.26 percent at $19.55.

Image Credit: Public Domain

Latest Ratings for MDSO

Jun 2019KeyBancDowngradesOverweightSector Weight
Jun 2019GuggenheimDowngradesBuyNeutral
Apr 2019Wells FargoDowngradesOutperformMarket Perform

View More Analyst Ratings for MDSO
View the Latest Analyst Ratings


Related Articles (ATHN + MDSO)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas Health Care Initiation Top Stories Analyst Ratings Trading Ideas Best of Benzinga

Latest Ratings

ABRRaymond JamesMaintains20.0
APTVRaymond JamesMaintains200.0
ANIPRaymond JamesMaintains60.0
VIACBarrington ResearchUpgrades50.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at